Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberté(R) Atom(TM) Stent system

    VANCOUVER, May 27 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP) today announced that its corporate partner, Boston Scientific
Corporation (NYSE:   BSX) has received approval from the U.S. Food and Drug
Administration (FDA) to market its TAXUS(R) Liberté(R) Atom(TM)
Paclitaxel-Eluting Coronary Stent System, a highly deliverable,
next-generation drug-eluting stent (DES) specifically designed for treating
small coronary vessels. It was approved for use in vessels as small as 2.25 mm
in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only
drug-eluting stents approved for small vessel use in the U.S. The Company
plans to begin a full U.S. launch of TAXUS Liberté Atom next month.
    "The rapid adoption of the TAXUS Express Atom Stent has confirmed the
need for this type of stenting option in the treatment of small-vessel
coronary artery disease," said Mark Turco, M.D., F.A.C.C., F.S.C.A.I.,
Director of the Center for Cardiac and Vascular Research at Washington
Adventist Hospital, Takoma Park, Maryland. "The TAXUS Liberté Atom Stent
provides clear design and deliverability advantages. Additionally, in the
TAXUS Atlas Small Vessel clinical trial, the TAXUS Liberté Atom Stent yielded
a two-year target lesion revascularization rate that was 60 percent less than
the TAXUS Express Atom Stent. I am pleased to be able to offer this option to
my patients."
    Data from numerous clinical studies have shown that an estimated 10
percent of patients undergoing percutaneous coronary interventions have small
vessels ((less than)2.5 mm). Until recently, many physicians were inclined to
implant bare-metal stents in these patients since they were the only approved
stenting option for small vessels. Last year's launch of the TAXUS Express
Atom Stent offered an alternative treatment choice for patients with small
vessels who will now have the additional option of the TAXUS Liberté Atom
    The TAXUS Liberté Stent features design improvements over the Company's
first-generation TAXUS Express Stent, including thinner struts to allow better
stent deliverability and conformability, as well as uniform stent geometry for
consistent lesion coverage and drug distribution.
    Boston Scientific offers the industry's widest range of coronary stent
sizes. The Company expects to expand its stent portfolio later this year with
the first 38 mm long DES, the TAXUS(R) Liberté(R) Long Stent, which is
currently under review with the FDA.
    TAXUS Stents have been evaluated by the industry's most extensive
randomized, controlled clinical trial program, with follow-up to five years in
some cases. These trial results have been supplemented by data on more than
35,000 patients enrolled in post-approval registries. To date, approximately
11 million Boston Scientific stents have been implanted globally, making them
the world's most frequently used stents.

    Forward Looking Statements

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2009 and beyond, our strategies
or future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research, development, product
and drug development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are taken into
account as part of our assumptions underlying these forward-looking statements
and include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing products or our
ability to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products sold by our partners;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement for
substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and
any other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from third
party challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission ("SEC") and
applicable Canadian regulatory authorities. For a more thorough discussion of
the risks associated with our business, see the "Risk Factors" section in our
annual report for the year ended December 31, 2008 filed with the SEC on Form
10-K, and our quarterly report for the three months ended March 31, 2009 filed
with the SEC on Form 10-Q.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at

For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890